kynurenine has been researched along with Lupus Erythematosus, Systemic in 13 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Type I and II interferons (IFNs) stimulate the KYN/TRP pathway, producing elevated QA/kynurenic acid (KA), a potential neurotoxic imbalance that may contribute to SLE-mediated cognitive dysfunction." | 8.12 | Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE. ( Anderson, EW; Aranow, C; Arazi, A; Diamond, B; Furie, RA; Goodwin, S; Jin, Y; Mackay, M; Roeser, J; Shih, A; Volpe, B, 2022) |
| " Type I and II interferons (IFNs) stimulate the KYN/TRP pathway, producing elevated QA/kynurenic acid (KA), a potential neurotoxic imbalance that may contribute to SLE-mediated cognitive dysfunction." | 4.12 | Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE. ( Anderson, EW; Aranow, C; Arazi, A; Diamond, B; Furie, RA; Goodwin, S; Jin, Y; Mackay, M; Roeser, J; Shih, A; Volpe, B, 2022) |
| "We have demonstrated recently that systemic lupus erythematosus (SLE) is activated during the sunny season as measured by the European Consensus Lupus Activity Measurement Index (ECLAM) activity score." | 1.34 | Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. ( Hasan, T; Hurme, M; Korpela, M; Oja, SS; Pertovaara, M; Raitala, A; Yli-Kerttula, U, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (38.46) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, EW | 4 |
| Fishbein, J | 1 |
| Hong, J | 1 |
| Roeser, J | 4 |
| Furie, RA | 4 |
| Aranow, C | 4 |
| Volpe, BT | 1 |
| Diamond, B | 4 |
| Mackay, M | 4 |
| Jin, Y | 3 |
| Shih, A | 3 |
| Arazi, A | 3 |
| Goodwin, S | 3 |
| Volpe, B | 3 |
| Lood, C | 1 |
| Tydén, H | 1 |
| Gullstrand, B | 1 |
| Klint, C | 1 |
| Wenglén, C | 1 |
| Nielsen, CT | 1 |
| Heegaard, NH | 1 |
| Jönsen, A | 1 |
| Kahn, R | 1 |
| Bengtsson, AA | 1 |
| Xiang, ZY | 1 |
| Tang, AG | 1 |
| Ren, YP | 1 |
| Zhou, QX | 1 |
| Luo, XB | 1 |
| Filippini, P | 1 |
| Del Papa, N | 1 |
| Sambataro, D | 1 |
| Del Bufalo, A | 1 |
| Locatelli, F | 1 |
| Rutella, S | 1 |
| PINALS, RS | 1 |
| BEETHAM, W | 1 |
| FISCHER, S | 1 |
| SCHROHENLOHER, R | 1 |
| Pertovaara, M | 1 |
| Hasan, T | 1 |
| Raitala, A | 1 |
| Oja, SS | 1 |
| Yli-Kerttula, U | 1 |
| Korpela, M | 1 |
| Hurme, M | 1 |
| Widner, B | 2 |
| Sepp, N | 2 |
| Kowald, E | 2 |
| Kind, S | 1 |
| Schmuth, M | 1 |
| Fuchs, D | 2 |
| Ortner, U | 1 |
| Wirleitner, B | 1 |
| Fritsch, P | 1 |
| Baier-Bitterlich, G | 1 |
| Chruściel, M | 1 |
| Calandra, P | 2 |
| Binazzi, M | 1 |
1 review available for kynurenine and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Emerging concepts on inhibitors of indoleamine 2,3-dioxygenase in rheumatic diseases.
Topics: Animals; Arthritis, Rheumatoid; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kyn | 2012 |
12 other studies available for kynurenine and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus.
Topics: Cognitive Dysfunction; Cross-Sectional Studies; Humans; Kynurenine; Lupus Erythematosus, Systemic; N | 2021 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Type I interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Antinuclear; Blood Platelets; Case-Control S | 2015 |
Simultaneous determination of serum tryptophan metabolites in patients with systemic lupus erythematosus by high performance liquid chromatography with fluorescence detection.
Topics: Adult; Chromatography, High Pressure Liquid; Female; Fluorescence; Humans; Kynurenic Acid; Kynurenin | 2010 |
TRYPTOPHAN METABOLISM IN RHEUMATIC DISEASE.
Topics: Amino Acids; Arthritis; Arthritis, Rheumatoid; Chromatography; Humans; Kynurenic Acid; Kynurenine; L | 1964 |
TRYPTOPHAN METABOLITE EXCRETION IN CONNECTIVE TISSUE DISEASES DEMONSTRATING A DIFFERENCE BETWEEN RHEUMATOID SPONDYLITIS AND RHEUMATOID ARTHRITIS.
Topics: Arthritis; Arthritis, Rheumatoid; Connective Tissue Diseases; Diagnosis, Differential; Humans; Kynur | 1964 |
Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season.
Topics: Adult; Female; Humans; Immune Tolerance; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lupus Ery | 2007 |
Degradation of tryptophan in patients with systemic lupus erythematosus.
Topics: Depression; Humans; Kynurenine; Lupus Erythematosus, Systemic; Neopterin; Reference Values; Tryptoph | 1999 |
Enhanced tryptophan degradation in systemic lupus erythematosus.
Topics: Adult; Aged; Female; Humans; Kynurenine; Lupus Erythematosus, Systemic; Male; Middle Aged; Neopterin | 2000 |
Changes resembling lupus erythematosus after prolonged treatment with Ro-4-4602, a potent inhibitor of 5-HTP-carboxyliase, in white rats.
Topics: 5-Hydroxytryptophan; Aminobenzoates; Animals; Carboxy-Lyases; Cholesterol; Creatinine; Female; Hydra | 1969 |
Tryptophan metabolism in man, rat and pig. Determination of tryptophan-pyrrolase and kinureninase in liver.
Topics: Adult; Animals; Dicarboxylic Acids; Erythema; Female; Humans; Hydrolases; Kynurenine; Lichen Planus; | 1972 |
Tryptophan to niacin pathway in lupus erythematosus.
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Kynurenine; Lupus Erythematosus, Systemic; Male; Mid | 1971 |